Highlights

  • Racura expanded HARNESS-1 through ethics approvals for additional Australian sites.
  • The company activated its first South Korean CPACS clinical trial site.
  • Both Phase 1 programs cleared their first dose cohorts without dose-limiting toxicities.
  • The developer ended September 2026 with AUD 30.735 million in cash.

Racura Oncology (ASX:RAC) is a clinical-stage biopharmaceutical company developing cancer treatments around its proprietary RC220 formulation of (E,E)-bisantrene. Its Q1FY27 report, released on 22 October 2026, followed an expanding clinical program through early safety reviews, additional trial sites and post-quarter dose escalation. The period ended with cash available to support committed activities into mid-calendar 2028.

HARNESS Gains Sites and Dose Clearance

The HARNESS-1 program evaluates RC220 with osimertinib in patients with EGFR-mutated non-small cell lung cancer. Ethics approval on 3 July 2026 enabled additional Australian trial sites to participate.

Sites in New South Wales and Victoria progressed towards governance and start-up activities, supporting broader patient access and recruitment. On 29 July, the first treated patient completed a safety review without dose-limiting toxicities or treatment-related safety concerns during the observation period.

The review recommended enrolling another patient at the same dose before escalation. That sequence continued after quarter-end: on 12 October, the trial received clearance to move to 100 mg/m² after neither of the two patients treated at 50 mg/m² showed dose-limiting toxicities or treatment-related safety concerns.

CPACS Extends Its Clinical Reach

The parallel CPACS Phase 1 trial combines RC220 with doxorubicin in patients with advanced solid tumours. Its first South Korean site activated on 1 September, with further sites scheduled to follow.

The expanded network was expected to support recruitment and trial progress. A 7 October presentation subsequently confirmed completion of the first dose cohort without dose-limiting toxicities and progression to the next RC220 dose level.

Patient enrolment continued across Australia, Hong Kong and South Korea. The program evaluates potential cardioprotective and anticancer benefits, with the reported milestones centred on early safety and continued dose evaluation.

Research Progress Reaches Beyond the Clinic

Alongside the trials, preclinical findings accepted for a September-announced conference presentation supported the G4-binding mechanism of (E,E)-bisantrene and its inhibition of MYC gene transcription.

The research underpinned the scientific rationale for RC220 across the EMILI, HARNESS and CPACS programs. The broader development portfolio included a Phase 2b/3 pivotal program in acute myeloid leukaemia and Phase 1a/b combination programs in lung cancer and solid tumours.

The company also added two clinical project managers focused on HARNESS-1 and EMILI, plus an associate medical director to support clinical development and medical strategy.

Cash Supports the Committed Program

Cash and equivalents closed Q1FY27 at AUD 30.735 million, down from AUD 34.290 million at the start of the quarter. Operating cash outflow reached AUD 3.542 million, with a further AUD 13,000 used in investing activities and no financing cash flows.

The activities report identified AUD 2.46 million directed towards research, development and drug manufacturing, representing 80% of its stated spending measure. In August, an additional AUD 117,875 tax incentive refund brought the total FY25 R&D refund to AUD 2.905 million.

At the reporting date, management expected cash to fund all committed activities into mid-calendar 2028. The cash flow appendix estimated 8.68 quarters of funding using the reported quarterly operating outflow.

Early Safety Leaves Further Questions

The findings covered initial cohorts and safety observation periods. They did not establish treatment efficacy or outcomes at higher doses. Continued recruitment, dose evaluation and subsequent clinical results remained central to assessing the programs as development advanced.